is a nitrogen-containing second generation BP, which was first used to treat Paget's disease in 1971 (http://drug.report/Alendronate/interactions/5/) (11).
In the second trial, one group received romosozumab-aqqg for 1 year and then a year of alendronate
, and the other group received 2 years of alendronate
, another oste oporosis therapy The romosozumab-aqqg arm had 50% less risk of vertebral fractures than did the alendronate-only arm, as well as reduced risk of nonvertebral fractures.
In the active-controlled ARCH study, the patients treated with Evenity for 12 months followed by 12 months of alendronate
experienced a significant reduction in the incidence of new vertebral fracture at 24 months.
therapy did not reduce the risk of fractures among women with osteopenia which contributed to a treatment gap for women with osteopenic T scores but strong risk factors for an osteoporotic fracture.
therapy did not reduce the risk of fractures among women with osteopenia, which contributed to a treatment gap for women with osteopenic T scores but strong risk factors for an osteoporotic fracture.
[USA], May 12 (ANI): The osteoporosis drug - alendronate
- may benefit your heart health, suggests a recent study.
The report, published in Journal of Bone and Mineral Research, showed that the drug Alendronate
could lower the risk of cardiovascular diseases by 67 per cent and heart attacks by 45 per cent within a year.
Radius Health presented results from "Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density, or BMD, in Patients Treated with Abaloparatide Followed by Alendronate
- Results from Phase 3 ACTIVExtend at ENDO 2018, the Endocrine Society's 100th Annual Meeting and Expo in Chicago.
Objectives: This study aims to investigate the effect of alendronate
sodium on trabecular bone structure in an osteoporotic rat model.
The present study was designed to evaluate the effect of Sodium Alendronate
(an oral bisphosphonate), on bone mineral density in patients with carcinoma prostate treated with hormonal manipulation.
After screening between September 2013 and March 2014, 240 participants were randomly assigned in a 1: 1 ratio to receive either alendronate
70 mg/week (alendronate
group, Merck Sharp & Dohme (Italia) S.p.A., J20130085), TCM prescription QiangGuYin granules 20g/day (QGY group, concentrated decoction, composed of Cornu Cervi Degelatinatum 20 g, honeysuckle stem 25 g, Caulis Spatholobi 25 g, Gentiana macrophylla 15 g, Radix Sileris 15 g, Nidus Vespae 20 g, cinnamon 10 g, Ligusticum wallichii 20 g, Astragalus membranaceus 30 g, Rhizoma Drynariae 20 g, Eucommia ulmoides 15 g, and Dipsacus asperoides 30 g, produced by Pharmaceutical Preparation Centre of the Second Affiliated Hospital of Heilongjiang University Of Chinese Medicine), or placebo (placebo group).